Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
Authors
Keywords
-
Journal
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume 32, Issue 3, Pages 372-381
Publisher
Wiley
Online
2017-08-28
DOI
10.1111/jdv.14542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.
- (2017) L. L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
- (2016) Varun Goel et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors
- (2016) Jocelyn Zhou et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
- (2016) Reinhard Dummer et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
- (2015) Aleksandar Sekulic et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
- (2015) Michael R Migden et al. LANCET ONCOLOGY
- Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
- (2015) Nicole Basset-Seguin et al. LANCET ONCOLOGY
- Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective
- (2014) J T Lear et al. BRITISH JOURNAL OF CANCER
- A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
- (2014) A. J. Wagner et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
- (2014) J. Goldman et al. CLINICAL CANCER RESEARCH
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
- (2014) J. Rodon et al. CLINICAL CANCER RESEARCH
- An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma
- (2014) Mina Sarah Ally et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study
- (2013) A. Italiano et al. ANNALS OF ONCOLOGY
- Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
- (2013) C. Danial et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
- (2013) A. Jimeno et al. CLINICAL CANCER RESEARCH
- Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib
- (2013) Anne Lynn S. Chang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
- (2012) Jean Y. Tang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Non-melanoma skin cancer
- (2010) Vishal Madan et al. LANCET
- Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
- (2010) Shifeng Pan et al. ACS Medicinal Chemistry Letters
- Review: Targeting the Hedgehog pathway in cancer
- (2010) Sachin Gupta et al. Therapeutic Advances in Medical Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now